M. D’Incan

A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid

P. Joly, Jean‐Claude Roujeau, Jacques Bénichou et al. · New England Journal of Medicine · 2002 · 614 citations

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 586 citations

Ritux 3, Pharmacology, Pharmacotherapy +2

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 569 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

A Single Cycle of Rituximab for the Treatment of Severe Pemphigus

P. Joly, Hugo Mouquet, Jean‐Claude Roujeau et al. · New England Journal of Medicine · 2007 · 460 citations

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Franz Trautinger, Robert Knobler, Rein Willemze et al. · European Journal of Cancer · 2006 · 415 citations · Full text

Immunodeficiencies, Pathology, Clinical Dermatology +4